Advantages and controversies of depot antipsychotics in the treatment of patients with schizophrenia

Breit, Sigrid; Hasler, Gregor (2016). Advantages and controversies of depot antipsychotics in the treatment of patients with schizophrenia. Nervenarzt, 87(7), pp. 719-723. Springer-Medizin-Verlag 10.1007/s00115-015-0021-9

[img]
Preview
Text
Breit_Hasler_2016_Depotantipsychotika.pdf - Published Version
Available under License Publisher holds Copyright.

Download (159kB) | Preview
[img]
Preview
Text
Breit_Hasler_2015_Depotantipsychotika Schizophrenie.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (129kB) | Preview

BACKGROUND

The objective of this article is to give an overview of the advantages and disadvantages of the use of depot antipsychotics in the treatment of schizophrenia. The focus is on efficacy, tolerability, relapse prevention, patient compliance and satisfaction compared to oral administration forms.

MATERIAL AND METHODS

A literature search was conducted in medical databases. The results of meta-analyses, randomized controlled trials and systematic reviews from the years 1999-2014 were included.

RESULTS AND DISCUSSION

Depot antipsychotics ensure maintenance of constant blood levels and a continuous medication delivery. The efficacy and tolerability of depot antipsychotics are comparable to oral administration forms. Due to an improved medication compliance a reduction of relapse and hospitalization rates can be achieved. This is a key focus for improving outcomes and reducing costs in the treatment of schizophrenia.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology
04 Faculty of Medicine > University Psychiatric Services > University Hospital of Psychiatry and Psychotherapy
04 Faculty of Medicine > University Psychiatric Services > University Hospital of Psychiatry and Psychotherapy > Healthcare Research

UniBE Contributor:

Breit, Sigrid, Hasler, Gregor

Subjects:

600 Technology > 610 Medicine & health
600 Technology

ISSN:

0028-2804

Publisher:

Springer-Medizin-Verlag

Language:

German

Submitter:

Gregor Hasler

Date Deposited:

07 Jan 2016 16:01

Last Modified:

05 Dec 2022 14:50

Publisher DOI:

10.1007/s00115-015-0021-9

PubMed ID:

26597275

Uncontrolled Keywords:

Compliance; Health costs; Relapse; Schizophrenia; Tolerability

BORIS DOI:

10.7892/boris.74433

URI:

https://boris.unibe.ch/id/eprint/74433

Actions (login required)

Edit item Edit item
Provide Feedback